retatrutide peptide trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Significantly Reduces Visceral Fat

meta-analysis: OR = 0.55, 95% CI [0.320.93])

This lifts the subcutaneous layer away from the underlying muscle, ensuring the medication deposits into fat rather than muscle tissue

115 Zealand Pharma

Walmart Zepbound vials via LillyDirect pickup: $349 a month for the 2.5 mg starting dose

LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist

A comprehensive analysis of 43,365 individuals from two US healthcare databases indicated that GLP-1 RAs do not elevate the risk of pulmonary aspiration during upper gastrointestinal endoscopy in patients with T2DM when compared to SGLT-2 inhibitors, yielding a pooled risk ratio of 0.98 (95% CI, 0.73 to 1.31) among GLP-1 RA users